Understanding your personal risk of breast cancer is one of the most valuable steps you can take for your long-term health. Risk is not destiny — knowing where you stand allows you and your specialist to make informed decisions about screening, surveillance, and, where appropriate, risk-reducing strategies.

At Breast & Surgical Oncology at The Poche Centre, our specialist breast surgeons have extensive experience in breast cancer risk assessment, genetic counselling referral, and the management of women and men at elevated risk. If you have concerns about your family history or personal risk factors, we can help you understand what they mean and what options are available to you.

How Common Is Breast Cancer?

Breast cancer is the most commonly diagnosed cancer in Australian women. Approximately one in seven Australian women will be diagnosed with breast cancer during their lifetime, and around 21,000 Australians are diagnosed each year.

Despite these numbers, the majority of breast cancers — around 95% — arise without a clearly identifiable inherited cause. Most women who develop breast cancer have no significant family history of the disease. Having no known risk factors does not mean you cannot develop breast cancer, and having multiple risk factors does not mean you will. Risk is a probability, not a certainty — and understanding it allows for smarter, more personalised decision-making.

Categories of Breast Cancer Risk

Breast cancer risk is generally categorised into three groups — average risk, moderately elevated risk, and high risk — based on a combination of personal, family, hormonal, lifestyle, and genetic factors. Your risk category determines the type and frequency of screening recommended for you.

Non-Modifiable Risk Factors

These are factors that cannot be changed but are important to understand as part of your overall risk picture.

Age is the single most significant risk factor for breast cancer. The risk increases steadily with age — the majority of breast cancers are diagnosed in women over 50, and the risk continues to rise throughout life. This is why the national BreastScreen Australia program targets women aged 50 to 74 for two-yearly free mammographic screening.

Being female — while men can and do develop breast cancer, women are around 100 times more likely to be diagnosed. Male breast cancer accounts for approximately 1% of all cases.

Dense breast tissue — women with dense breasts (more glandular and fibrous tissue relative to fatty tissue) have a higher risk of developing breast cancer and may also find that cancers are harder to detect on standard mammogram alone. Breast density is reported on every mammogram and your specialist can advise on what it means for your screening approach.

Hormonal and reproductive factors — the longer breast tissue is exposed to oestrogen over a lifetime, the higher the cumulative risk. Factors that increase oestrogen exposure include early onset of menstruation (before age 12), late menopause (after age 55), never having been pregnant, and having a first pregnancy after the age of 30. These factors each carry a modest individual effect but can be cumulative.

Previous breast conditions — certain high-risk breast lesions found on biopsy are associated with an increased future risk of breast cancer. These include atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS), and ductal carcinoma in situ (DCIS). A personal history of invasive breast cancer also significantly increases the risk of a second primary breast cancer.

Previous chest radiotherapy — women who received radiotherapy to the chest area (for example, for Hodgkin's lymphoma) before the age of 30 have a significantly elevated lifetime risk of breast cancer and are eligible for intensive surveillance programs.

Modifiable Risk Factors — What You Can Control

While many risk factors cannot be changed, a meaningful proportion of breast cancer risk is attributable to lifestyle factors that are within your control. Making positive changes in these areas can reduce your risk — not just of breast cancer, but of a wide range of other health conditions.

Alcohol — alcohol is one of the most clearly established modifiable risk factors for breast cancer. Even moderate alcohol consumption increases risk, and the relationship is dose-dependent — the more you drink, the higher the risk. The Cancer Council Australia recommends limiting alcohol consumption as much as possible. If you do drink, staying within low-risk guidelines (no more than one standard drink per day) is advisable.

Weight and physical activity — being overweight or obese, particularly after menopause, is associated with a meaningfully elevated breast cancer risk. This is thought to be driven by higher circulating oestrogen levels in postmenopausal women, as fat tissue produces oestrogen. Maintaining a healthy weight through a balanced diet and regular physical activity is one of the most impactful lifestyle modifications for reducing breast cancer risk. Regular exercise independently lowers risk, regardless of weight.

Smoking — while the relationship between smoking and breast cancer is less direct than with some other cancers, smoking is a significant risk to overall health and should be avoided.

Hormonal medications — prolonged use of combined (oestrogen and progestogen) menopause hormone therapy (MHT, previously known as hormone replacement therapy - HRT) is associated with a modest but real increase in breast cancer risk. The risk appears to reduce after stopping MHT. The oral contraceptive pill is associated with a very small increase in risk that returns to baseline within around 10 years of stopping. These medications carry genuine benefits for many women, and decisions about their use should be made in full discussion with your doctor, weighing individual risks and benefits.

Reproductive factors — having children, particularly at a younger age (before 30), and breastfeeding are both associated with a modest reduction in breast cancer risk in the general population. Breastfeeding is thought to reduce risk through its effects on hormonal cycling and breast tissue differentiation.

How Is Nipple Discharge Assessed?

Clinical History

Your specialist will ask detailed questions about your discharge — when it started, whether it is spontaneous or only on expression, which breast and how many duct openings are involved, what colour it is, whether there are any associated symptoms, and your full medication history. This history alone can often narrow the likely cause considerably.

Clinical Examination

A thorough breast examination includes gentle assessment of the nipple to determine which duct opening the discharge is coming from, whether a mass can be felt in the subareolar area, and whether any associated skin or nipple changes are present.

Imaging

Mammography and/or ultrasound are performed to assess the breast and subareolar duct system for any structural abnormality. In some cases, particularly where a duct papilloma is suspected, ultrasound can identify the papilloma directly within the dilated duct.

MRI may be recommended where discharge is persistent, imaging is inconclusive, or where there is clinical concern about malignancy that has not been clarified by other means.

Cytology

Cytology or testing of the discharge fluid is unreliable and is generally not recommended for the investigation of nipple discharge

Biopsy

If imaging identifies a suspicious lesion, a core biopsy under ultrasound guidance will be recommended to obtain a tissue diagnosis. Where no abnormality is identified on imaging but discharge is persistent, spontaneous, and blood-stained, surgical exploration of the duct may be required even in the absence of a visible lesion, as small papillomas and early cancers can be beyond the resolution of standard imaging.

Family History and Genetic Risk

For approximately 5% of women, breast cancer risk is significantly elevated due to an inherited gene mutation that can be passed through families from either parent. Understanding your family history is an important part of risk assessment.

Factors in your family history that increase concern include:

• Multiple relatives on the same side of the family diagnosed with breast or ovarian cancer
• Breast cancer diagnosed at a young age (before 50, and particularly before 40)
• A male relative diagnosed with breast cancer
• A family member known to carry a BRCA1, BRCA2, or other high-risk gene mutation
• A personal or family history of both breast and ovarian cancer
• Ashkenazi Jewish ancestry (which carries a higher prevalence of BRCA mutations)
• A family member diagnosed with bilateral (both sides) breast cancer

Having one or more of these features does not automatically mean you carry a high-risk gene mutation — but it does warrant a detailed family history assessment.  Our specialists are expert in risk factor assessment and can organise genetic testing if you fulfil certain criteria for testing, or refer you to one of our genetic specialist colleagues should this be warranted.

BRCA1 and BRCA2

The best-known inherited breast cancer genes are BRCA1 and BRCA2. Women who carry a pathogenic mutation in BRCA1 have a lifetime risk of breast cancer of approximately 50–72%, and a significantly elevated risk of ovarian cancer. BRCA2 carriers have a lifetime breast cancer risk of approximately 45–69%, with a lower but still elevated ovarian cancer risk.

These mutations are not exclusively a female concern — men who carry BRCA2 mutations have an elevated risk of breast cancer, prostate cancer, and pancreatic cancer, and can pass the mutation to their children.

Other High-Risk Genes

Beyond BRCA1 and BRCA2, a growing number of other gene mutations are now recognised as carrying elevated breast cancer risk, including PALB2, CHEK2, ATM, CDH1, and PTEN. Genetic testing panels now routinely assess multiple genes simultaneously, allowing a more comprehensive picture of inherited risk.

Genetic Counselling and Testing

If your family history raises concern, your GP or specialist can refer you to a familial cancer service or clinical geneticist. Genetic counselling involves a detailed assessment of your family history, an explanation of what genetic testing can and cannot tell you, and — where testing is appropriate — analysis of a blood or saliva sample for relevant gene mutations.

Genetic testing results have significant implications not just for you but for your blood relatives, and it is important that the process is supported by appropriate counselling before and after testing.

Screening for Women at Elevated or High Risk

The appropriate screening program for you depends on your level of risk. For women at average risk, two-yearly mammographic screening through BreastScreen Australia (for women aged 50–74) is the recommended standard. Women outside this age range can still access mammographic screening through their GP.  If you have dense breasts (Category C or D) supplemental screening such as ultrasound, MRI or contrast mammogram may be indicated too, but best to discuss with your GP

For women at moderately elevated or high risk, a more intensive and personalised surveillance program is recommended, which may include:

Annual mammography — commencing at a younger age than the national program, often from age 40 or earlier depending on individual risk.  For women with dense breasts (Category C or D density) mammogram alone is not sufficient to use as a screening tool and another imaging modality such as ultrasound, MRI or contrast mammogram should be performed.

Annual breast MRI — MRI is significantly more sensitive than mammography in high-risk women, particularly those with dense breast tissue or those under 50. Research has shown MRI can detect breast cancer at a very early, highly treatable stage in this population. MRI is recommended annually for women with a BRCA1 or BRCA2 mutation or equivalent high risk, typically from age 30.

Contrast Mammogram - has similar sensitivity as MRI, is a quicker and easier test to have than an MRI but there is currently no medicare rebate.

Breast ultrasound — used as a supplementary tool when mammogram findings are inconclusive or as an adjunct in younger women with dense tissue. Not recommended as a standalone screening test.

Clinical breast examination — regular examination by a specialist forms part of the surveillance program for high-risk women, in conjunction with imaging.

Self-examination — while breast self-examination has not been proven to reduce mortality in the general population, familiarity with your own breasts means you are more likely to notice a change that is new or different. Any new change should prompt prompt GP review and, if appropriate, specialist referral.

Risk-Reducing Options for High-Risk Women

For women identified as being at significantly elevated risk — particularly those with a confirmed BRCA1, BRCA2, or equivalent mutation — a range of risk-reducing strategies can be considered. These are deeply personal decisions that should be made in the context of careful specialist counselling and in accordance with your own values and preferences. There is no single right answer.

Risk-reducing (prophylactic) mastectomy — surgical removal of both breasts reduces the risk of breast cancer by approximately 95%. It cannot eliminate risk entirely, as a small amount of breast tissue always remains. Breast reconstruction is available and can be performed at the same time as the mastectomy. This is a significant surgical decision and is not right for everyone, but for women who have seen multiple family members affected by breast cancer or who find the uncertainty of surveillance deeply distressing, it can provide substantial peace of mind as well as meaningful risk reduction.

Risk-reducing salpingo-oophorectomy (RRSO) — surgical removal of the ovaries and fallopian tubes reduces ovarian cancer risk by approximately 80–85% in BRCA carriers and also reduces breast cancer risk, particularly when performed before natural menopause. It does induce a surgical menopause, and the implications of this (including bone health, cardiovascular risk, and quality of life) need to be carefully discussed and managed.

A combined approach — some women choose risk-reducing ovarian surgery combined with intensive breast surveillance (rather than prophylactic mastectomy). Others choose mastectomy. Some pursue neither and opt for close surveillance alone. All of these are reasonable and supported approaches. The important thing is that the decision is fully informed and reflects your own priorities.

Chemoprevention (medication to reduce risk) — certain medications have been shown to reduce breast cancer risk in women at elevated risk:

Tamoxifen — a five-year course of tamoxifen has been shown to reduce the risk of oestrogen receptor-positive breast cancer by approximately 50% in high-risk premenopausal women. It carries a small risk of serious side effects including blood clots and, rarely, endometrial cancer, and is not suitable for everyone.

Raloxifene — similar in action to tamoxifen, raloxifene is approved for breast cancer risk reduction in postmenopausal women and reduces risk by approximately 60%. It has the additional benefit of reducing osteoporosis risk. It carries a lower risk of endometrial cancer than tamoxifen.

Aromatase inhibitors — medications such as exemestane and anastrozole have also shown significant risk reduction in postmenopausal women and are increasingly being used in high-risk settings.

Whether chemoprevention is appropriate for you, and which agent is most suitable, depends on your menopausal status, other health factors, and personal preferences. These are medications with real benefits and real side effects, and their use should always be guided by a specialist.

Your Breast Cancer Risk at a Glance

The following summarises the key risk factors and their approximate magnitude of effect:

Factors that increase risk:

• Age over 50
• Dense breast tissue on mammogram
• BMI over 25 (particularly post-menopause)
• More than one standard alcoholic drink per day
• Early menstruation (before age 12)
• Late menopause (after age 55)
• Use of combined HRT
• Previous radiotherapy to the chest (e.g. for Hodgkin's lymphoma)
• Personal history of atypical ductal hyperplasia, LCIS, DCIS, or prior breast cancer
• Family history: three or more first- or second-degree relatives with breast or ovarian cancer, particularly diagnosed under 50
• Ashkenazi Jewish ancestry
• Confirmed BRCA1, BRCA2, PALB2, or equivalent gene mutation

Factors that reduce risk:

• Giving birth before age 30
• Breastfeeding
• Regular physical activity
• Maintaining a healthy weight
• Limiting alcohol consumption
• Risk-reducing surgery (where appropriate)

Online tool IPrevent can be used to assess your breast cancer risk https://iprevent.net.au.  This may help guide your breast screening recommendations

Speak to a Specialist About Your Risk

If you are concerned about your personal or family history of breast cancer, a formal risk assessment with a specialist breast surgeon is a worthwhile and empowering step. It puts you in control — with a clear understanding of your level of risk, a personalised screening plan, and knowledge of the options available to you.

Our team at Breast & Surgical Oncology at The Poche Centre has deep expertise in breast cancer risk assessment and the management of women at elevated or high risk. We can assess your history, advise on appropriate screening, refer to familial cancer services where needed, and support you through the decisions that follow.